Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival

Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. 2021. Early PSA Change after [177Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival. Cancers (Basel). 2021 Dec 29;14(1):149. doi: 10.3390/cancers14010149.

Categorised in:

This post was written by Heike Ufheil